(firstQuint)Registry Study for Talimogene Laherparepvec.

 A registry study is to evaluate the overall survival, use of subsequent anti-cancer therapy, and the long-term safety of subjects who have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type.

 Follow-Up will occur every 3 months.

.

 Registry Study for Talimogene Laherparepvec@highlight

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials